Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.

[1]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[2]  S. Saab,et al.  Spotlight on grazoprevir–elbasvir once-daily combination and its potential in the treatment of hepatitis C , 2016, Drug design, development and therapy.

[3]  M. Manns,et al.  Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  T. Asselah,et al.  Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectives , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[5]  Aasld Idsa Hcv Guidance Panel.  Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[6]  P. Thuluvath,et al.  All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study , 2015, Hepatology.

[7]  Lai Wei,et al.  Performance Comparison of the Versant HCV Genotype 2.0 Assay (LiPA) and the Abbott Realtime HCV Genotype II Assay for Detecting Hepatitis C Virus Genotype 6 , 2014, Journal of Clinical Microbiology.

[8]  O. Weiland,et al.  ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. , 2014, Gastroenterology.

[9]  A. Flaxman,et al.  Global Distribution and Prevalence of Hepatitis C Virus Genotypes , 2014, Hepatology.

[10]  Thomas Berg,et al.  ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.

[11]  R. Marinho,et al.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.

[12]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[13]  G. Esmat,et al.  The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm , 2014, Journal of viral hepatitis.

[14]  Eoin Coakley,et al.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[15]  W. Kim,et al.  The impact of hepatitis C burden: an evidence‐based approach , 2014, Alimentary pharmacology & therapeutics.

[16]  T. Pilot‐Matias,et al.  Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. , 2014, The New England journal of medicine.

[17]  R. Bruno,et al.  Who is more likely to respond to dual treatment with pegylated‐interferon and ribavirin for chronic hepatitis C? A gender‐oriented analysis , 2013, Journal of viral hepatitis.

[18]  M. Manns,et al.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.

[19]  William M. Lee,et al.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. , 2010, Gastroenterology.

[20]  B. Haagmans,et al.  Genotyping Hepatitis C Viruses from Southeast Asia by a Novel Line Probe Assay That Simultaneously Detects Core and 5′ Untranslated Regions , 2006, Journal of Clinical Microbiology.

[21]  J. Chapman.  The Medical Letter on Drugs and Therapeutics. , 1964 .

[22]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2016. , 2017, Journal of hepatology.

[23]  Stefan Zeuzem,et al.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.